Princeton-based Advaxis Inc., a biotechnology company focused on immunotherapy products, announced Wednesday it has appointed Molly Henderson its new executive vice president and chief financial officer, effective June 6.
Henderson was previously at Cedar Cliff LLC as its financial and business consultant. Previously, she was CFO at Iovance Biotherapeutics Inc.
“We welcome Molly to the Advaxis team and look forward to her contributions,” said Ken Berlin, president and CEO. “Molly has significant experience as a public company CFO in the health care industry, including immuno-oncology, and in managing the capital efficiency and financial requirements of a development-stage biotechnology company like Advaxis. We are very pleased to add Molly to our executive management team.”
“I have spent the majority of my professional career supporting the development of exciting growth companies in the healthcare industry, including managing the finance function, raising capital and creating an infrastructure for success,” Henderson said.
Prior to Iovance, Henderson was chief business and financial officer, senior vice president of VirtualScopics Inc. for 10 years.
